D-0761-2023 Class II Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0761-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on May 9, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications; during stability testing The recall status is terminated (terminated Feb 27, 2024). Affected quantity: 5,344 Bottles.

Recall details

Product Type
Drugs
Report Date
May 31, 2023
Initiation Date
May 9, 2023
Termination Date
Feb 27, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,344 Bottles

Product description

buPROPrion Hydrochloride Extended-Release Tablets, USP (SR) 150 mg, 60 Tablets, Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ, Manufactured by: Sun Pharmaceutical Industries Limited, Gujrat, India, NDC 47335-737-86

Reason for recall

Failed Dissolution Specifications; during stability testing

Distribution pattern

Nationwide in the U.S.A

Code information

Lots: HAC2240A, Exp 05/2023; HAC3162A, Exp 07/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0761-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0761-2023. Report a data issue: hello@regdatalab.com.